Approval · Notice of Compliance 1831 · 1999
GEMZAR: Notice of Compliance 1831
Issued August 19, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1831
- Date
- August 19, 1999
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: in comibination with cisplatin for the treatment of patients with locally advanced or metastatic non-small cell lung cancer
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GEMZAR | Not yet assigned | — |
Medicinal ingredients
- GEMCITABINE HYDROCHLORIDE 200 MG per VIAL
- GEMCITABINE HYDROCHLORIDE 1,000 MG per VIAL